Medical Marijuana, Inc. Subsidiary Kannaway® Announces Positive Preliminary Results of Validcare Clinical Study on CBD Liver Toxicity

SAN DIEGO, CA, March 23, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, reports today that its subsidiary Kannaway® participated in, and today announces the recent positive results, of the Validcare clinical study. The study used Kannaway®’s hemp-derived cannabidiol (CBD) products as a part of its efforts to meet the Food and Drug Administration (FDA)’s request for data on the use of botanical CBD with regard to potential liver toxicity issues, which seem to occur with the pharmaceutical version of CBD.

According to Validcare’s team of principal investigators, the study showed no evidence of liver toxicity in the 839 trial participants who ingested oral forms of hemp-derived CBD for a minimum of 60 days. The investigators met with the Food and Drug Administration (FDA) Cannabis Product Council (formerly known as the Cannabis Work Group) on Monday, March 15, to share these findings and answer the organization’s March 5, 2020, request for science-based data to help determine the appropriate regulatory path for hemp-derived CBD products. Blood markers for ALT (Alanine Aminotransferase), AST (Aspartate Aminotransferase), ALP (Alkaline Phosphatase), and Bilirubin levels were examined during the study.

“These study results help support the work that we’ve been doing in Mexico and Brazil to study CBD’s safety and efficacy,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We hope to continue to participate in similar future studies so that the world can continue to have expanded access to high-quality botanical products. I am glad to see participating stakeholders with longer-term visions banding together to make industry-wide progress that ultimately will benefit end consumers. Our company is involved with similar research in Europe in conjunction with the European Industrial Hemp Association (EIHA).”

Brands that participated in this study provided funding, product, certificates of authenticity, and assisted with the recruitment of adult US-based consumers. The use of Validcare’s decentralized clinical research platform and partnership with national laboratories enabled participants and principal investigators to successfully complete this first cohort, despite the pandemic, and compile and deliver results to brands and the FDA within six weeks.

“As the creators of some of the first testing measures for the entire CBD industry, many that are still used by other companies today, we are proud to be a part of this study and continue to be leaders in CBD safety testing,” said Kannaway® CEO Blake Schroeder. “Providing the highest-quality, safest products on the market is something we are proud of.”

About Kannaway®
Kannaway® is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products.

About Medical Marijuana, Inc.

We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Neuropathix, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.

Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at or by visiting To see Medical Marijuana, Inc.’s corporate video, click here.

Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.


These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.


Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.


Public Relations Contact:
Kathryn Brown
Account Supervisor
CMW Media
P. 858-264-6600
[email protected]

Investor Relations Contact:
P. (858) 283-4016
[email protected]